Pregnant women have frequently been excluded from or de-prioritized in clinical research initiatives due to a multitude of factors, such as the complex physiology of pregnant women, the risk studies may pose to the fetus, and the classification of pregnant…
The purpose of this Training Manual is to provide information for you and your community. This information can be used to advocate for access to prevention and diagnosis of, and care and treatment for, hepatitis C virus (HCV). The manual is written by and for people who are not medical specialists. We’re treatment activists who learned about HCV because it was a problem for people in our communities.
Gilead Sciences is limiting access to Truvada as a component of nonoccupational postexposure prophylaxis (nPEP) through its patient assistance program to once in a lifetime, with hardship review criteria and processes for subsequent prescriptions that have not been clearly articulated and are likely a considerable barrier to nPEP by uninsured and underinsured U.S. residents.
TAG mourns the loss of an inspirational, tireless, catalytic leader of our movement. Dr. Krim understood the gravity of the epidemic, in its earliest and darkest days, and was driven by her own remarkable intelligence, fierce commitment to civil rights and social justice, extraordinary social and political networks, and true grit to galvanize funders, scientists, policy leaders, and activists toward a single cause: ending HIV and AIDS as a threat to humanity.
TAG participated in a hearing in Geneva, Switzerland to brief members of the Human Rights Council on human rights concerns in the United Arab Emirates (UAE).
November – December 2017 Examples of media coverage: Lung cancer drug may be early clue in hunt for HIV cure – The Independent, November 30, 2017 Cancer drug offers tantalising hope for HIV cure – The Guardian, November 30, 2017…
On November 29, 2017, Treatment Action Group (TAG) hosted a webinar on suboptimal immune recovery despite HIV suppression by antiretroviral therapy. Presented by Richard Jefferys, TAG’s Basic Science, Vaccines and Cure Project Director, the webinar reviewed the possible causes and…
Now is the time to end the HIV/AIDS epidemic in America’s southern states. Over the past four years, innovative Ending the Epidemic (EtE) plans have emerged in several jurisdictions across the nation following New York’s 2014 announcement that it will…
TAG comments submitted to the Strategic Planning Team at the Office of the Assistant Secretary for Planning and Evaluation regarding the HHS Strategic Plan FY 2018-2022. The HHS Strategic Plan should set a precedent for reducing the burden of disease nationally through its focus on access to affordable treatment, advancement of research, implementation of evidence-based interventions, expansion of populations served, and inclusion of all stakeholders.
TAG’s comments on the Divisions of AIDS (DAIDS) in advance of the recompetition of its clinical trials networks.